Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK0524 in seasonal allergic rhinitis
NCT00533208Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2003
- Primary completion
- Oct 2003
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of laropiprant in seasonal allergic rhinitis (SAR) (4 arms), sponsored by Merck & Co. Primary endpoint: Daytime Nasal Symptoms Score at 2 weeks. Started Jul 2003; status: completed.
02
Drugs
laropiprant
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT00533208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00533208.